Drug Profile
Research programme: anticancer therapeutics - Seoul pharma
Alternative Names: KAIARI MOST Genome Research Foundation Project; Rho X projectLatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Seoul Pharma
- Class Small molecules
- Mechanism of Action Rho GTP-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in South Korea
- 08 Oct 2015 Preclinical trials in Cancer in South Korea (unspecified route)